| # | Drug | Count |
|---|---|---|
| 0 | CYCLOPHOSPHAMIDE | 52 |
| 1 | CYCLOPHOSPHAMIDE FOR INJECTION | 52 |
| 2 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 52 |
| 3 | RITUXIMAB | 52 |
| 4 | PREDNISONE | 44 |
| 5 | DOXORUBICIN | 37 |
| 6 | OBINUTUZUMAB | 32 |
| 7 | VINCRISTINE SULFATE | 28 |
| 8 | DOXORUBICIN HYDROCHLORIDE | 21 |
| 9 | ETOPOSIDE | 16 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BROMINE | 2 | 0.0036 |
| 1 | ZANUBRUTINIB | 14 | 0.0031 |
| 2 | OBINUTUZUMAB | 32 | 0.0019 |
| 3 | MOSUNETUZUMAB | 2 | 0.0018 |
| 4 | BENDAMUSTINE HYDROCHLORIDE | 10 | 0.0012 |
| 5 | LISOCABTAGENE MARALEUCEL | 1 | 0.0011 |
| 6 | POLATUZUMAB VEDOTIN | 11 | 0.0011 |
| 7 | VINCRISTINE SULFATE | 28 | 0.0009 |
| 8 | BENDAMUSTINE HCL | 13 | 0.0008 |
| 9 | MITOXANTRONE HYDROCHLORIDE | 5 | 0.0008 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 1 | 0.0002 |
| 1 | BCL-2 Inhibitor [EPC] | 14 | 0.0002 |
| 2 | Alkylating Drug [EPC] | 53 | 0.0002 |
| 3 | Topoisomerase Inhibitor [EPC] | 16 | 0.0002 |
| 4 | CD19-directed Chimeric Antigen Receptor [EPC] | 2 | 0.0002 |
| 5 | CD20-directed Cytolytic Antibody [EPC] | 53 | 0.0002 |
| 6 | Platinum-based Drug [EPC] | 14 | 0.0001 |
| 7 | Corticosteroid [EPC] | 54 | 0.0000 |
| 8 | Nucleoside Metabolic Inhibitor [EPC] | 6 | 0.0000 |
| 9 | Thalidomide Analog [EPC] | 10 | 0.0000 |